Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Labeled oxazaphosphorines for applications in mass spectrometry studies. 2. Synthesis of deuterium-labeled 2-dechloroethylcyclophosphamides and 2- and 3-dechloroethylifosfamides.

Springer JB, Colvin OM, Ludeman SM.

J Labelled Comp Radiopharm. 2014 Feb;57(2):110-4. doi: 10.1002/jlcr.3142. Epub 2013 Dec 5.

PMID:
24307455
2.

Glutathione levels in human tumors.

Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM.

Biomarkers. 2012 Dec;17(8):671-91. doi: 10.3109/1354750X.2012.715672. Epub 2012 Aug 20. Review.

3.

Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.

Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS.

Mol Cancer Ther. 2007 Aug;6(8):2280-9. Epub 2007 Aug 1.

4.

Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training.

Campbell LC, Keefe FJ, Scipio C, McKee DC, Edwards CL, Herman SH, Johnson LE, Colvin OM, McBride CM, Donatucci C.

Cancer. 2007 Jan 15;109(2 Suppl):414-24.

5.

Chemodosimetry of in vivo tumor liposomal drug concentration using MRI.

Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW.

Magn Reson Med. 2006 Nov;56(5):1011-8.

6.

New approach to the activation of anti-cancer pro-drugs by metalloporphyrin-based cytochrome P450 mimics in all-aqueous biologically relevant system.

Spasojević I, Colvin OM, Warshany KR, Batinić-Haberle I.

J Inorg Biochem. 2006 Nov;100(11):1897-902. Epub 2006 Aug 5.

PMID:
16965820
7.

Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex.

Adams DJ, da Silva MW, Flowers JL, Kohlhagen G, Pommier Y, Colvin OM, Manikumar G, Wani MC.

Cancer Chemother Pharmacol. 2006 Jan;57(2):135-44. Epub 2005 Aug 23.

PMID:
16151810
8.

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

Petros WP, Hopkins PJ, Spruill S, Broadwater G, Vredenburgh JJ, Colvin OM, Peters WP, Jones RB, Hall J, Marks JR.

J Clin Oncol. 2005 Sep 1;23(25):6117-25. Epub 2005 Aug 8.

PMID:
16087946
9.

Intrastrand base-stacking buttresses widening of major groove in interstrand cross-linked B-DNA.

da Silva MW, Bierbryer RG, Wilds CJ, Noronha AM, Colvin OM, Miller PS, Gamcsik MP.

Bioorg Med Chem. 2005 Jul 15;13(14):4580-7.

PMID:
15953553
10.

Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ.

Clin Cancer Res. 2005 Jun 1;11(11):4225-33.

11.

Structure, flexibility, and repair of two different orientations of the same alkyl interstrand DNA cross-link.

Noll DM, Webba da Silva M, Noronha AM, Wilds CJ, Colvin OM, Gamcsik MP, Miller PS.

Biochemistry. 2005 May 10;44(18):6764-75.

PMID:
15865422
12.

Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.

Storms RW, Green PD, Safford KM, Niedzwiecki D, Cogle CR, Colvin OM, Chao NJ, Rice HE, Smith CA.

Blood. 2005 Jul 1;106(1):95-102. Epub 2005 Mar 24.

13.

Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life.

Campbell LC, Keefe FJ, McKee DC, Edwards CL, Herman SH, Johnson LE, Colvin OM, McBride CM, Donattuci CF.

J Pain Symptom Manage. 2004 Nov;28(5):433-44.

PMID:
15504620
14.

Accommodation of mispair aligned N3T-ethyl-N3T DNA interstrand cross link.

da Silva MW, Wilds CJ, Noronha AM, Colvin OM, Miller PS, Gamcsik MP.

Biochemistry. 2004 Oct 5;43(39):12549-54.

PMID:
15449944
15.

1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards.

Springer JB, Chang YH, Koo KI, Colvin OM, Colvin ME, Dolan ME, Delaney SM, Flowers JL, Ludeman SM.

Chem Res Toxicol. 2004 Sep;17(9):1217-26.

PMID:
15377155
16.

Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.

Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS.

Mol Cancer Ther. 2004 Sep;3(9):1127-35.

17.

In-transit melanoma: the role of alkylating-agent resistance in regional therapy.

Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS.

J Am Coll Surg. 2004 Sep;199(3):419-27.

PMID:
15325612
18.

Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium.

Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, de Groot JF, Hickner RC, Cavus I, Grossman SA, Colvin OM.

Neuro Oncol. 2004 Jan;6(1):65-74. Erratum in: Neuro-oncol. 2004 Apr;6(2):172.

19.

Adventures with an enigmatic anticancer drug.

Colvin OM.

Cancer Biol Ther. 2003 May-Jun;2(3):301-3. No abstract available.

PMID:
12878871
20.

In vitro induction of fetal hemoglobin in human erythroid progenitor cells.

Ho JA, Pickens CV, Gamcsik MP, Colvin OM, Ware RE.

Exp Hematol. 2003 Jul;31(7):586-91. Erratum in: Exp Hematol. 2003 Aug;31(8):741. Gamscik Michael P [corrected to Gamcsik Michael P].

PMID:
12842703
21.

The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.

Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ.

Cancer Chemother Pharmacol. 2003 Sep;52(3):253-61. Epub 2003 Jun 3.

PMID:
12783198
22.

Solution structure of a DNA duplex containing mispair-aligned N4C-ethyl-N4C interstrand cross-linked cytosines.

Webba da Silva M, Noronha AM, Noll DM, Miller PS, Colvin OM, Gamcsik MP.

Biochemistry. 2002 Dec 24;41(51):15181-8.

PMID:
12484755
23.

Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.

Friedman HS, Johnson SP, Colvin OM.

Cancer Treat Res. 2002;112:199-209. Review. No abstract available.

PMID:
12481718
24.

O6-benzylguanine-mediated enhancement of chemotherapy.

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME.

Mol Cancer Ther. 2002 Sep;1(11):943-8.

25.

Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.

Bacolod MD, Johnson SP, Ali-Osman F, Modrich P, Bullock NS, Colvin OM, Bigner DD, Friedman HS.

Mol Cancer Ther. 2002 Jul;1(9):727-36.

26.

Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex.

Gamcsik MP, Kasibhatla MS, Adams DJ, Flowers JL, Colvin OM, Manikumar G, Wani M, Wall ME, Kohlhagen G, Pommier Y.

Mol Cancer Ther. 2001 Nov;1(1):11-20.

27.

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS.

J Clin Oncol. 2002 May 1;20(9):2277-83.

PMID:
11980998
28.

Exposure to a deuterated analogue of phenylbutyrate retards S-phase progression in HT-29 colon cancer cells.

Clarke KO, Ludeman SM, Springer JB, Colvin OM, Lea MA, Harrison LE.

J Pharm Sci. 2002 Apr;91(4):1054-64.

PMID:
11948544
29.

Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies.

Balu N, Gamcsik MP, Colvin ME, Colvin OM, Dolan ME, Ludeman SM.

Chem Res Toxicol. 2002 Mar;15(3):380-7.

PMID:
11896686
30.

Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.

Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP.

Clin Cancer Res. 2002 Mar;8(3):698-705.

31.

Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.

Adams DJ, Levesque MC, Weinberg JB, Smith KL, Flowers JL, Moore J, Colvin OM, Silber R.

Leukemia. 2001 Dec;15(12):1852-9.

PMID:
11753605
32.

Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

Springer JB, Colvin ME, Colvin OM, Ludeman SM.

J Org Chem. 1998 Oct 16;63(21):7218-7222.

PMID:
11672363
33.

Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS.

Clin Cancer Res. 2001 Jun;7(6):1497-504.

34.

Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.

Ichikawa T, Petros WP, Ludeman SM, Fangmeier J, Hochberg FH, Colvin OM, Chiocca EA.

Cancer Res. 2001 Feb 1;61(3):864-8.

35.

Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.

Flowers JL, Ludeman SM, Gamcsik MP, Colvin OM, Shao KL, Boal JH, Springer JB, Adams DJ.

Cancer Chemother Pharmacol. 2000;45(4):335-44.

PMID:
10755323
36.

Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.

Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.

Cancer Res. 2000 Dec 15;60(24):6950-7.

37.

Camptothecin analogues with enhanced antitumor activity at acidic pH.

Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani MC, Wall ME.

Cancer Chemother Pharmacol. 2000;46(4):263-71.

PMID:
11052623
38.

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME.

J Clin Oncol. 2000 Oct 15;18(20):3522-8.

PMID:
11032594
39.

Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.

Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS.

J Neurooncol. 1999;44(3):233-41.

PMID:
10720203
40.

Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.

Cohen DP, Adams DJ, Flowers JL, Wall ME, Wani MC, Manikumar G, Colvin OM, Silber R.

Leuk Res. 1999 Nov;23(11):1061-70.

PMID:
10576512
41.

An overview of cyclophosphamide development and clinical applications.

Colvin OM.

Curr Pharm Des. 1999 Aug;5(8):555-60. Review.

PMID:
10469891
42.

Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity.

Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C.

Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9118-23.

43.

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL.

J Clin Oncol. 1999 May;17(5):1516-25.

PMID:
10334539
44.

Metabolic jeopardy with high-dose cyclophosphamide?--not so fast.

Petros WP, Colvin OM.

Clin Cancer Res. 1999 Apr;5(4):723-4. No abstract available.

45.

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.

Friedman HS, Pegg AE, Johnson SP, Loktionova NA, Dolan ME, Modrich P, Moschel RC, Struck R, Brent TP, Ludeman S, Bullock N, Kilborn C, Keir S, Dong Q, Bigner DD, Colvin OM.

Cancer Chemother Pharmacol. 1999;43(1):80-5.

PMID:
9923545
46.

Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR).

Dong Q, Johnson SP, Colvin OM, Bullock N, Kilborn C, Runyon G, Sullivan DM, Easton J, Bigner DD, Nahta R, Marks J, Modrich P, Friedman HS.

Cancer Chemother Pharmacol. 1999;43(1):73-9.

PMID:
9923544
47.

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL.

J Clin Oncol. 1998 Dec;16(12):3851-7.

PMID:
9850030
48.

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.

Hanley ML, Elion GB, Colvin OM, Modrich PL, Keir S, Adams DJ, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1998;42(6):479-82.

PMID:
9788574
49.

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1998;41(6):485-90.

PMID:
9554593
50.

Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain.

Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, Saltzman WM.

Cancer Res. 1998 Feb 15;58(4):672-84.

Supplemental Content

Loading ...
Support Center